SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-039861
Filing Date
2023-11-08
Accepted
2023-11-08 13:15:13
Documents
66
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1487799
2 ex31-1.htm EX-31.1 18078
3 ex31-2.htm EX-31.2 17773
4 ex32-1.htm EX-32.1 5780
5 ex32-2.htm EX-32.2 5903
6 form10-q_001.jpg GRAPHIC 88557
7 form10-q_002.jpg GRAPHIC 168012
  Complete submission text file 0001493152-23-039861.txt   6914551

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE lpcn-20230930.xsd EX-101.SCH 40308
9 XBRL CALCULATION FILE lpcn-20230930_cal.xml EX-101.CAL 49910
10 XBRL DEFINITION FILE lpcn-20230930_def.xml EX-101.DEF 180828
11 XBRL LABEL FILE lpcn-20230930_lab.xml EX-101.LAB 348748
12 XBRL PRESENTATION FILE lpcn-20230930_pre.xml EX-101.PRE 277813
60 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1015944
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36357 | Film No.: 231387003
SIC: 2834 Pharmaceutical Preparations